This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Definitive Healthcare Corp. (DH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Definitive Healthcare Corp. (DH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Definitive Healthcare Corp. (DH) Soars 7.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Definitive Healthcare Corp. (DH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Alcon (ALC) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.
3 Medical Product Stocks Set to Outpace Q2 Earnings Estimates
by Indrajit Bandyopadhyay
Medical Product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how NEOG, PDCO and DH are poised ahead of their earnings release.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -49.02% and 45.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Definitive Healthcare Corp. (DH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Definitive Healthcare Corp. (DH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Is a Beat Likely for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter 2023 results are expected to reflect solid performance in the Pharmaceutical segment.
Computer Programs and Systems (CPSI) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of -33.33% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of -13.79% and 0.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Augmedix, Inc. (AUGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Augmedix, Inc. (AUGX) delivered earnings and revenue surprises of 7.69% and 3.55%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 75.76% and 8.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Definitive Healthcare, Clover Health and Augmedix
by Zacks Equity Research
Healthcare, Clover Health and Augmedix are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Consider From a Prospering Industry
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Definitive Healthcare (DH), Clover Health Investments (CLOV) and Augmedix (AUGX) are expected to gain from new normal trends.
Definitive Healthcare Corp. (DH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 2.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of -4.35% and 6.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Tabula Rasa Healthcare (TRHC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Definitive Healthcare Corp. (DH) Reports Next Week: What You Should Expect
by Zacks Equity Research
Definitive Healthcare Corp. (DH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva
by Zacks Equity Research
AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.
4 Toxic Stocks That Are Detrimental to Your Portfolio's Health
by Lavina Shahu
Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.
Zacks.com featured highlights CoStar, Definitive Healthcare, Montauk Renewables and Westrock Coffee
by Zacks Equity Research
CoStar, Definitive Healthcare, Montauk Renewables and Westrock Coffee have been highlighted in this Screen of The Week article.
4 Toxic Stocks That You Should Eliminate From Your Portfolio
by Rimmi Singhi
Similar to identifying stocks with growth potential, pinpointing toxic stocks and discarding them at the right time is the key to avoid losses. CSGP, DH, MNTK and WEST are few toxic stocks you should dump now.
How Much Upside is Left in Definitive Healthcare Corp. (DH)? Wall Street Analysts Think 29.75%
by Zacks Equity Research
The consensus price target hints at a 29.8% upside potential for Definitive Healthcare Corp. (DH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Implied Volatility Surging for Definitive Healthcare (DH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Definitive Healthcare (DH) stock based on the movements in the options market lately.
Definitive Healthcare Corp. (DH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 1.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?